Added to YB: 2026-02-27
Pitch date: 2026-02-24
MXCT [neutral]
MaxCyte, Inc.
+45.92%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Market Cap
$109.3M
Pitch Price
$0.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.64
P/E
-2.78
EV/Sales
0.62
Sector
Life Sciences Tools and Services
Category
value
MaxCyte: Trading at less than book and then some $mxct
MXCT (update): Electroporation instrument provider for ex-vivo cell/gene therapies down 80% YoY to <0.5x tangible book. Core rev ~75% recurring (licenses/consumables), high margins. Collects ~1% royalties on Casgevy sales + milestones. 5 programs entering pivotal trials next 6-18mo. $106M cash, no debt, $10-15M cash burn. Risks: ex-vivo sentiment shift to in-vivo, weak Casgevy launch, science risk, customer funding issues. Insiders buying 97%.
Read full article (6 min)